Two recommendations:
🌟against administering convalescent plasma for non-severe covid-19.
🌟against administering convalescent plasma for severe or critical covid-19, except in the context of a clinical trial.
Now with a 🔥🔥 website with evidence readily accessible: covid19lnma.com.
🌟For non-severe illness:
- No benefit for critical or important outcomes, including mortality and mechanical ventilation
- Potential for harm
- Resource requirements / practical issues (donor identification & testing, plasma collection / storage / transportation, administration)
🌟For severe/critical illness:
- Low certainty evidence for mortality, mechanical ventilation, etc.
- Potential for harm.
- Resource requirements (similar issues, though may be easier to administer in hospitalized patients).
- More research needed to reduce uncertainty.
This work contributes to collaborative living guidance produced by @WHO and the #MAGIC Evidence Ecosystem on drugs to prevent #COVID19, also published via @bmj_latest.
This is an incredible cross-collaborative effort - honoured and lucky to be part of it.